S&P Futures
3,403.50+10.00(+0.29%)Dow Futures
27,655.00+74.00(+0.27%)Nasdaq Futures
11,535.00+42.75(+0.37%)
Aridis Pharmaceuticals, Inc. (ARDS)
Chart Events
Performance Outlook
| Previous Close | 7.77 |
| Open | 8.00 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 800 |
| Day's Range | 7.00 - 8.00 |
| 52 Week Range | 3.80 - 10.18 |
| Volume | 20,185 |
| Avg. Volume | 11,363 |
| Market Cap | 64.605M |
| Beta (5Y Monthly) | 0.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.70 |
| Earnings Date | Aug 11, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.60 |
- PR Newswire
Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 Patients
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced the development of a highly neutralizing monoclonal antibody AR-711, discovered from convalescent COVID-19 patients, that successfully eliminated all detectable SARS-CoV-2 virus in infected animals at substantially lower doses than parenterally administered (injected) COVID-19 monoclonal antibodies ("mAb"). The potency of AR-711 and its direct delivery to the lungs by inhaled administration may facilitate broader treatment coverage and dose sparing not achievable by parenteral administration.
- PR Newswire
Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (the "Company"), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that it has entered into a securities purchase agreement with certain institutional investors with extensive backgrounds in life sciences and biotechnology investing to purchase in a registered direct offering 1,134,470 shares of common stock for $7.4925 per share.
- PR Newswire
Aridis Announces Agreement with the FDA on Updated Phase 2 Clinical Trial Design for AR-501
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced it has reached an agreement with the US Food and Drug Administration (FDA) to simplify the Company's AR-501 Phase 2 trial design for the treatment of chronic lung infections associated with cystic fibrosis (CF).
